Last Update: Jul 16, 2026
Real-World Characteristics, Treatment Patterns, and Outcomes Among Adults With mCRPC Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
ClinicalTrials.gov Identifier:
NCT07677267
Novartis Reference Number:CAAA617A1US30
See if you Pre-qualify
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

The aim of this study is to assess treatment patterns, characteristics, and clinical outcomes among adults with metastatic castration-resistant prostate cancer (mCRPC) who have previously received ≥1 androgen receptor pathway inhibitor (ARPI), ≥1 taxane, and 177Lu-PSMA-617 in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.

Prostatic Neoplasms, Castration-Resistant
Recruiting
1067
Jun 30, 2026
Nov 30, 2026
Male
18 Years - 115 Years (Adult, Older Adult)

Eligibility Criteria

Inclusion criteria:

* Evidence of 177Lu-PSMA-617 use on or after 01 January 2021.
* Evidence of treatment with ≥1 ARPI, before 177Lu-PSMA-617.
* Evidence of treatment with ≥1 taxane, before or after 177Lu-PSMA-617.
* Diagnosis of mCRPC prior to or on the index date. The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617.
* Age ≥18 years at index.

Exclusion criteria:

• None.

Novartis

Recruiting

East Hanover,New Jersey,07936,United States

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

+41613241111